Psychosocial Stressors at Work Linked to Increased Risk for A-Fib
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 14, 2024 -- Psychosocial stressors at work, defined by job strain and effort-reward imbalance (ERI) at work, are associated with an increased risk for atrial fibrillation (AF), according to a study published online Aug. 14 in the Journal of the American Heart Association.
Edwige Tiwa Diffo, from Quebec-Laval University in Quebec City, Canada, and colleagues examined the separate and combined effect of psychosocial stressors at work from the job strain and ERI models on AF incidence in a prospective cohort study involving 5,926 white-collar workers free of cardiovascular disease at baseline and followed for 18 years. Validated instruments were used to assess job strain (high psychological demands combined with low decision latitude) and ERI.
The researchers identified 186 incident AF events over 18 years. In fully adjusted models controlled for socioeconomic characteristics and life-related and clinical risk factors, workers exposed to job strain and ERI had an increased risk for AF (hazard ratios, 1.83 and 1.44, respectively). An almost twofold increase in AF risk was seen with combined exposure to job strain and ERI (hazard ratio, 1.97).
"A workplace intervention aiming to reduce job strain and ERI exposures was shown to be effective to reduce blood pressure means and hypertension prevalence among workers," the authors write. "Therefore, such interventions may be effective to reduce the burden associated with AF at the population level."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-15 07:15
Read more
- Pandemic-Linked Worldwide Declines in Childhood Vaccination Not Yet Recovered
- FDA Approves Hympavzi for Hemophilia
- High Rates of Hep C Seen for Patients Presenting to ED With Opioid Overdose
- COVID-19 Pandemic-Linked Increase in Alcohol Use Persisting
- Protega Pharmaceuticals Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
- Quitting Smoking After Cancer Diagnosis Boosts Survival by Up to 26%
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions